Skip to content
Peptide research

Tripeptide-29

Also known as Collagen Fragment · Gly-Pro-Hyp
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

A tripeptide mimicking collagen's Gly-Pro-Hyp motif, marketed to boost skin collagen via fibroblast signaling. Evidence for better skin hydration and elasticity with oral use is mixed and comes mainly from collagen mixtures; wrinkle and AGE claims rest on thin, low-confidence data. Safety looks mild (rare allergy, occasional GI upset, an unestablished platelet interaction), but long-term topical data are limited. Not an approved drug; sold in cosmetics subject to applicable safety and labeling requirements.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Stimulation of type I collagen synthesis via fibroblast signaling

    Medium

    Human RCT found increased dermal collagen density, mechanism supported, but not tested on this exact sequence.

  • Improved skin hydration and elasticity (oral supplementation)

    Medium

    Multiple human RCTs show consistent hydration gains, though elasticity results are less consistent and industry funded.

  • Reduction of facial wrinkles and fine lines

    Low

    Human RCTs are mixed, with several showing no significant wrinkle reduction versus placebo.

Evidence limits

Evidence Level
Moderate

Human evidence mainly concerns collagen mixtures rather than isolated Tripeptide-29. Oral results vary by formulation and outcome, and results differ across trials. The 2021 placebo-controlled trial found reduced water loss after adjustment, without significant overall between-group improvements in hydration, elasticity, or wrinkles. A 2022 topical pilot study (PMID 35163025) in 22 women reported improvements in wrinkles, elasticity, density, and reduced AGE accumulation after 4 weeks, but it was uncontrolled and not randomized, so it cannot establish efficacy of isolated Tripeptide-29. Oral studies detect Gly-Pro-Hyp in human blood; direct skin-distribution data come from animal experiments. In vitro evidence is extensive, with well-characterized fibroblast activation via TGF-beta/Smad and MAPK/ERK pathways. A 6-month open-label trial (PMID 27725401) also reported cardiovascular marker improvements. No serious adverse events were reported across these studies. The evidence base draws on decades of collagen biology research on the Gly-Pro-Hyp motif, though large independent RCTs testing topical Tripeptide-29 as a sole active remain limited.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Allergic or sensitivity reaction (very rare)

    Low
  • Platelet interaction not established for isolated Tripeptide-29

    Theoretical
  • Limited long-term topical safety data

    Low
  • Gastrointestinal discomfort (oral supplementation)

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.